MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Avita Therapeutics Inc

Gesloten

5.37 3.47

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

5.37

Max

5.47

Belangrijke statistieken

By Trading Economics

Inkomsten

-2.3M

-14M

Verkoop

108K

19M

EPS

-0.826

Winstmarge

-74.857

Werknemers

260

EBITDA

-9.9M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+179.89% upside

Dividenden

By Dow Jones

Volgende Winsten

7 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-104M

140M

Vorige openingsprijs

1.9

Vorige sluitingsprijs

5.37

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Avita Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 jul 2025, 23:55 UTC

Marktinformatie

Gold Edges Lower on Possible Position Adjustments -- Market Talk

6 jul 2025, 22:35 UTC

Acquisities, Fusies, Overnames

South32 Expects to Complete Transaction in Late 2025

6 jul 2025, 22:35 UTC

Acquisities, Fusies, Overnames

South32: CoreX to Make Future Cash Payments of Up to US$100 Million for Cerro Matoso

6 jul 2025, 22:34 UTC

Acquisities, Fusies, Overnames

South32 Agrees to Sell Cerro Matoso Nickel Operation to Unit of CoreX Holding

5 jul 2025, 04:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

4 jul 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

4 jul 2025, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

4 jul 2025, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

4 jul 2025, 20:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

4 jul 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

4 jul 2025, 16:20 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

4 jul 2025, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

4 jul 2025, 16:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

4 jul 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

4 jul 2025, 15:57 UTC

Marktinformatie

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 jul 2025, 15:49 UTC

Marktinformatie

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 jul 2025, 15:49 UTC

Acquisities, Fusies, Overnames

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 jul 2025, 15:49 UTC

Acquisities, Fusies, Overnames

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 jul 2025, 15:49 UTC

Acquisities, Fusies, Overnames

Credit Agricole Received All Required Authorizations

4 jul 2025, 15:48 UTC

Acquisities, Fusies, Overnames

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 jul 2025, 15:47 UTC

Acquisities, Fusies, Overnames

Credit Agricole: Agreement Was Announced on Dec. 19

4 jul 2025, 15:47 UTC

Acquisities, Fusies, Overnames

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 jul 2025, 15:46 UTC

Acquisities, Fusies, Overnames

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 jul 2025, 14:30 UTC

Acquisities, Fusies, Overnames

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 jul 2025, 13:53 UTC

Marktinformatie

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 jul 2025, 13:41 UTC

Marktinformatie

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 jul 2025, 13:41 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

4 jul 2025, 13:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

4 jul 2025, 12:37 UTC

Marktinformatie

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 jul 2025, 12:37 UTC

Marktinformatie

Fund Manager Roundup: U.S. Treasurys in Focus -2-

Peer Vergelijking

Prijswijziging

Avita Therapeutics Inc Prognose

Koersdoel

By TipRanks

179.89% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 15.17 USD  179.89%

Hoogste 19 USD

Laagste 12.5 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Avita Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Technische score

By Trading Central

8.83 / 9.77Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Weak Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.